Catalyst Pharmaceutical Inc. (CPRX)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Catalyst Pharmaceutical Inc. (CPRX)
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
Key Insights
Critical company metrics and information
Share Price
$21.96Market Cap
$2.62 BillionTotal Outstanding Shares
119.27 Million SharesTotal Employees
167Dividend
No dividendIPO Date
November 8, 2006SIC Description
Pharmaceutical PreparationsHomepage
https://www.catalystpharma.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow | $321.36 Million |
| Net Cash Flow From Investing Activities, Continuing | $-38.79 Million |
| Net Cash Flow From Financing Activities | $135.57 Million |
| Net Cash Flow From Financing Activities, Continuing | $135.57 Million |
| Net Cash Flow From Operating Activities, Continuing | $224.58 Million |
| Net Cash Flow From Investing Activities | $-38.79 Million |
| Net Cash Flow From Operating Activities | $224.58 Million |
| Net Cash Flow, Continuing | $321.36 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Available To Common Stockholders, Basic | $142.80 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Other Operating Expenses | $37.09 Million |
| Selling, General, and Administrative Expenses | $175.58 Million |
| Income/Loss From Continuing Operations After Tax | $142.80 Million |
| Costs And Expenses | $271.69 Million |
| Income/Loss From Continuing Operations Before Tax | $188.79 Million |
| Basic Earnings Per Share | $1.25 |
| Revenues | $460.48 Million |
| Gross Profit | $397.47 Million |
| Basic Average Shares | $236.57 Million |
| Operating Income/Loss | $173.97 Million |
| Net Income/Loss | $142.80 Million |
| Cost Of Revenue | $63.01 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Income Tax Expense/Benefit | $45.99 Million |
| Benefits Costs and Expenses | $271.69 Million |
| Net Income/Loss Attributable To Parent | $142.80 Million |
| Diluted Average Shares | $249.44 Million |
| Operating Expenses | $223.50 Million |
| Research and Development | $10.82 Million |
| Diluted Earnings Per Share | $1.18 |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Current Liabilities | $85.82 Million |
| Noncurrent Liabilities | $5.67 Million |
| Fixed Assets | $1.38 Million |
| Other Current Assets | $518.98 Million |
| Assets | $772.01 Million |
| Wages | $8.01 Million |
| Liabilities And Equity | $772.01 Million |
| Current Liabilities | $105.39 Million |
| Current Assets | $539.00 Million |
| Liabilities | $111.07 Million |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Inventory | $20.02 Million |
| Accounts Payable | $11.56 Million |
| Other Non-current Assets | $231.63 Million |
| Equity | $660.94 Million |
| Equity Attributable To Parent | $660.94 Million |
| Noncurrent Assets | $233.01 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.